Crystal forms of crisaborole in free form and preparation method and use thereof

ABSTRACT

The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

CROSS REFERENCE TO PRIOR APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.16/099,839 filed Nov. 8, 2018, now pending, which is a 35 U.S.C. 371National Stage of International Application No. PCT/CN2017/083631 filedMay 9, 2017, which claims the benefit of Chinese Application No.CN201610301832.6 filed May 9, 2016, the entire disclosures of each areherein incorporated by reference.

TECHNICAL FIELD

The present invention relates to a pharmaceutical crystal technicalfield, and particularly, to crystal forms of crisaborole in free formand preparation method and use thereof.

BACKGROUND ART

Polycrystalline form or polycrystalline phenomenon is an inherentattribute of some molecules or molecular compositions. Same moleculesmay form different crystals due to different arrangements, and thesecrystals have different crystalline structures and physical properties,for example, such as solubility, stability, thermal property, mechanicalproperty, purification ability, X-ray diffraction pattern, IR absorptionpattern, Raman spectrum and solid state NMR. One or more methods foranalysis or detection can be used to distinguish different crystal formsof same molecules or molecular compositions.

It is found that novel crystal forms of pharmaceutically activeingredients (including anhydrates, hydrates, and solvates) may producemore workable advantages or provide materials having better physical andchemical characteristics, e.g., better bioavailability, better storagestability, easiness to be processed and treated, and easiness to bepurified, or as an intermediate crystal form that can be easilyconverted into other crystal forms. Some novel crystal forms ofpharmaceutically useful compounds also can help medicines to improvetheir properties. Thus, the novel crystal forms can expand selectiveforms of raw materials in the pharmaceuticals, e.g., improveddissolution, improved storage time limit, and more easiness to beprocessed.

Psoriasis and allergic dermatitis are non-infectious inflammatorydiseases with a chronic and recurrent course of disease. At present,although some therapies can be used to control these diseases, othertherapies are still in study. Appropriate therapies can relieve symptomsand prolong attack intervals. Crisaborole (also called as AN-2728) is akind of locally-administrated boron-containing compound developed byAnacor Pharmaceuticals Inc., which can inhibit the activity of PDE4,thereby inhibiting the release of TNFalpha, IL-12, IL-23 and othercytokines. Crisaborole has a good therapeutic effect on dermatoses suchas psoriasis, allergic dermatitis, etc., and it is approved by theAmerican FDA on Dec. 14, 2016. Crisaborole has the chemical name of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrile,and it is represented by the following chemical formula (I):

At present, there is no report regarding crystal forms of crisaborole inthe prior art. Thus, it is necessary to comprehensively andsystematically screen the polycrystalline forms of crisaborole, so as toselect the crystal forms having beneficial properties that can be usedfor developments of crisaborole products.

The inventors have surprisingly found out four crystal forms ofcrisaborole during researches. The crystal forms of crisaborole asprovided in the invention have good stability, low moisture absorption,homogenous particle size distribution, and a solubility that is in linewith medical requirements, and they can be stably stored, therebyavoiding crystal transitions of medicines during developments. Thus,these crystal forms have great values to be developed.

DESCRIPTIONS OF THE INVENTION

Directed to the deficiencies in the prior art, the objective of theinvention is to provide crystal forms of crisaborole and the preparationmethod and use thereof.

According to the objective of the invention, the invention is providedwith a crystal form I of crisaborole in free form (hereafter called as“crystal form I”).

With Cu—Kα irradiations, the X-ray powder diffraction of the crystalform I has the characteristic peaks at the diffraction angles 2θ:15.3°±0.2°, 26.1°±0.2°, 14.1°±0.2°.

In a preferred embodiment according to the invention, the X-ray powderdiffraction of the crystal form I has the characteristic peaks at thediffraction angles 2θ: 18.1°±0.2°, 24.8°±0.2°, 16.0°±0.2°.

In another preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form I has the characteristic peaks atthe diffraction angles 2θ: 28.4°±0.2°, 21.4°±0.2°, 6.0°±0.2°.

In a further preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form I has the characteristic peaks atthe diffraction angles 2θ: 15.3°±0.2°, 26.1°±0.2°, 14.1°±0.2°,18.1°±0.2°, 24.8°±0.2°, 16.0°±0.2, 28.4°±0.2°, 21.4°±0.2°, 6.0°±0.2°.

Non-limitedly, in a specific embodiment according to the invention, theX-ray powder diffraction pattern of the crystal form I is shown in FIG.1.

According to the objective of the invention, the invention is furtherprovided with a method of preparing the crystal form I, comprising thefollowing steps:

1) solids of crisaborole in free form are dissolved in a single volatilesolvent until the resultant mixture is clear, and the resultant mixtureperforms volatile crystallization, to produce solids of crystal form I,wherein the single volatile solvent is selected from alkyl nitriles,alkyl ethers, halogenated hydrocarbons and esters, wherein:

-   -   the alkyl nitrile solvent is acetonitrile,    -   the alkyl ether solvent is methyl(t-butyl) ether,    -   the halogenated hydrocarbon solvent is chlorinated hydrocarbon,        and preferably, the chlorinated hydrocarbon is selected from        chloroform and dichloromethane, and    -   the ester solvent is ethyl acetate; and    -   wherein the volatile crystallization is conducted at room        temperature, or

2) solids of crisaborole in free form are suspended in a single solventor a mixed solvent to produce a suspension, and the suspension isstirred, subjected to centrifugal separation, and dried, to produce thesolids of crystal form I, wherein: the single solvent comprises, but notlimited to, water and aromatic hydrocarbons, preferably water andtoluene,

-   -   the mixed solvent is a mixed solvent of water with a further        solvent selected from the group of alcohols, alkyl nitriles,        esters, ketones, amides, cyclic ethers or dimethyl sulfoxide,        wherein the volume ratio of water to the further solvent is in        the range between 4:3 and 5:1; or    -   the mixed solvent is a mixed solvent of saturated fatty        hydrocarbons with ketones, esters, cyclic ethers, halogenated        hydrocarbons or alcohols, wherein the volume ratio of the        saturated fatty hydrocarbons to the ketones, the esters, the        cyclic ethers, the halogenated hydrocarbons or the alcohols is        preferably in the range from 5:4 to 7:1; or    -   the mixed solvent is a mixed solvent of aromatic hydrocarbons        with halogenated hydrocarbons, wherein the volume ratio of the        aromatic hydrocarbons to the halogenated hydrocarbons is        preferably 5:4.

Preferably, the mixed solvent is a mixed solvent of water with methanol,acetonitrile, isopropyl acetate, 1,4-dioxane, acetone, dimethylformamide or dimethyl sulfoxide.

Preferably, the mixed solvent is a mixed solvent of n-heptane withmethyl isobutyl ketone, ethyl acetate, 2-methyltetrahydrofuran,chloroform or ethanol.

Preferably, the mixed solvent is a mixed solvent of toluene anddichloromethane.

The temperature is preferably from room temperature to 50° C.

According to the objective of the invention, the invention is providedwith crystal form II of Crisaborole in free form (hereafter called as“crystal form II”).

With Cu—Kα irradiations, the X-ray powder diffraction of the crystalform II has the characteristic peaks at the diffraction angles 2θ:20.8°±0.2°, 16.6°±0.2°, 22.6°±0.2°.

In a preferred embodiment according to the invention, the X-ray powderdiffraction of the crystal form II has the characteristic peaks at thediffraction angles 2θ: 27.9°±0.2°, 21.8°±0.2°, 17.6°±0.2°.

In another preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form II has the characteristic peaksat the diffraction angles 2θ: 18.4°±0.2°, 21.4°±0.2°, 23.1°±0.2°.

In a further preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form II has the characteristic peaksat the diffraction angles 2θ: 20.8°±0.2°, 18.8°±0.2°, 22.6°±0.2°,27.9°±0.2°, 21.8°±0.2°, 17.6°±0.2°, 18.4°±0.2°, 21.4°±0.2°, 23.1°±0.2°.

Non-limitedly, in a specific embodiment according to the invention, theX-ray powder diffraction pattern of the crystal form II is shown in FIG.4.

According to the objective of the invention, the invention is furtherprovided with a method of preparing the crystal form II, comprising thefollowing steps:

1) solids of crisaborole in free form are suspended in a mixed solventof water and an alcohol to produce a suspension, and the suspension isstirred, subjected to centrifugal separation and dried, to provide thesolids of the crystal form II, wherein the water to alcohol volume ratiois 1:1, wherein

-   -   the alcohol is preferably methanol, and    -   the stirring and separating steps each are conducted at room        temperature; or

2) solids of crisaborole in free form are dissolved in a positivesolvent, and then a reverse solvent is added thereto; the resultantmixture crystallized while being stirred, separated and dried, toproduce the solids of crystal form II, wherein the solids of crisaborolein free form are present in the positive solvent in a state that thesolids are dissolved until the resultant mixture is clear or in a statethat the solids are completely dissolved, and the reverse solvent isadded until solids are produced;

-   -   the positive solvent includes, but not limited to, alcohols,        ketones, cyclic ethers, amides, and dimethyl sulfoxide, and the        inverse solvent is preferably water, wherein:    -   the alcohol solvent is isopropanol,    -   the ketone solvent is acetone,    -   the cyclic ether solvent is selected from tetrahydrofuran, and        1,4-dioxane, and    -   the amide solvent is dimethylformamide; and    -   the stirring crystallizing step and the separating step both are        conducted at room temperature.

According to the objective of the invention, the invention is providedwith crystal form III of crisaborole in free form (hereafter called as“crystal form III”).

With Cu—Kα irradiations, the X-ray powder diffraction of the crystalform III has the characteristic peaks at the diffraction angles 2θ:20.6°±0.2°, 27.8°±0.2°, 18.6°±0.2°.

In a preferred embodiment according to the invention, the X-ray powderdiffraction of the crystal form III has the characteristic peaks at thediffraction angles 2θ: 13.6°±0.2°, 19.5°±0.2°, 21.7°±0.2°.

In another preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form III has the characteristic peaksat the diffraction angles 2θ: 21.3°±0.2°, 16.3°±0.2°, 22.5°±0.2°.

In a further preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form III has the characteristic peaksat the diffraction angles 2θ: 20.6°±0.2°, 27.8°±0.2°, 18.6°±0.2°,13.6±0.2°, 19.5°±0.2°, 21.7°±0.2°, 21.3°±0.2°, 16.3°±0.2°, 22.5°±0.2°.

Non-limitedly, in a specific embodiment according to the invention, theX-ray powder diffraction pattern of the crystal form III is shown inFIG. 7.

According to the objective of the invention, the invention is furtherprovided with a method of preparing the crystal form III, comprising thefollowing steps: solids of crisaborole in free form are dissolved in aketone solvent until the resultant mixture is clear, and the resultantmixture is subjected to volatile crystallization,

-   -   to produce the solids of crystal form III, wherein    -   the ketone solvent is preferably acetone, and    -   the volatile crystallization is conducted at room temperature.

According to the objective of the invention, the invention is providedwith crystal form IV of Crisaborole in free form (hereafter called as“crystal form IV”).

With Cu—Kα irradiations, the X-ray powder diffraction of the crystalform IV has the characteristic peaks at the diffraction angles 2θ:20.0°±0.2°, 18.6°±0.2°, 26.4°±0.2°.

In a preferred embodiment according to the invention, the X-ray powderdiffraction of the crystal form IV has the characteristic peaks at thediffraction angles 2θ: 5.3°±0.2°, 24.9°±0.2°, 23.2°±0.2°.

In another preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form IV has the characteristic peaksat the diffraction angles 2θ: 17.2°±0.2°, 21.4°±0.2°, 13.0°±0.2°.

In a further preferred embodiment according to the invention, the X-raypowder diffraction of the crystal form IV has the characteristic peaksat the diffraction angles 2θ: 20.0°±0.2°, 18.6°±0.2°, 26.4°±0.2°,5.3°±0.2°, 24.9°±0.2°, 23.2°±0.2°, 17.2°±0.2°, 21.4°±0.2°, 13.0°±0.2°.

Non-limitedly, in a specific embodiment according to the invention, theX-ray powder diffraction pattern of the crystal form IV is shown in FIG.10.

According to the objective of the invention, the invention is furtherprovided with a method of preparing the crystal form IV, the methodcomprising the following steps: solids of crisaborole in free form, thecrystal form I, the crystal form II or the crystal form III are heatedto a temperature from 120° C. to 150° C., to produce the solids ofcrystal form IV. Preferably, the temperature is at 130° C. to 145° C.

According to the objective of the invention, the invention is furtherprovided with a pharmaceutical composition, comprising a therapeuticallyeffective dose and/or a prophylactically effective dose of the crystalform I of crisaborole in free form, or the crystal form II ofcrisaborole in free form, or the crystal form III of crisaborole in freeform, or the crystal form IV of crisaborole in free form, as abovedescribed, or a combination of these crystal forms, and at least onepharmaceutically acceptable carrier or vehicle.

The invention relates to use of the crystal form I of crisaborole infree form, or the crystal form II of crisaborole in free form, or thecrystal form III of crisaborole in free form, or the crystal form IV ofcrisaborole in free form, or a combination of these crystal forms in theproduction of medicine formulations for treating psoriasis and allergicdermatitis.

The term “room temperature” in the invention refers to the temperaturefrom 15 to 25° C.

In the invention, the “2θ” expresses the same meaning as that of the“2theta”.

The “stirring” is accomplished by using conventional methods in the art,e.g., magnetic stirring or mechanical stirring, with the stirring speedof 50 to 1800 r/m, preferably from 300 to 900 r/m, and most preferably500 r/m.

The “separation” is accomplished by using conventional methods in theart, e.g., centrifugation or filtration. The “centrifugation” comprisesthe following operations: a sample to be separated is placed in acentrifugal tube and centrifuged in a speed of 10000 r/m until allsolids therein are deposited at the bottom of the centrifugal tube.

Unless specifically described, the “drying” may be carried out at roomtemperature or a higher temperature. The drying temperature is in therange of from room temperature to about 60° C., or from room temperatureto 40° C., or from room temperature to 50° C., The drying time is in therange from 2 to 48 hours or the drying continues overnight. The dryingis carried out in a fume hood, a forced air oven or a vacuum oven.

In the invention, the “crystals” or “crystal forms” refer to those asconfirmed by X-ray diffraction pattern. Thus, a person skilled in theart could understand that the physical and chemical properties asdiscussed here may be characterized, wherein experimental errors dependon conditions of apparatus, sample preparations and sample purity. Inparticular, a person skilled in the art could well know that the X-raydiffraction pattern usually will vary with changes in conditions ofassociated apparatus. It should be particularly pointed out that therelative intensity of the X-ray diffraction pattern also varies with thechanges in experimental conditions. Thus, the order of peak intensitiescannot be used as a unique or crucial factor. In addition, thediffraction angle 2θ usually allows the error at ±0.2°. Moreover, due toeffects of experimental factors, such as sample height, peak angles willbe deviated in a whole, and usually, certain deviations are allowable.Hence, a person skilled in the art can understand that the X-raydiffraction pattern of a crystal form in the invention does not have tobe in line with the X-ray diffraction pattern in the examples asindicated here. Any crystal forms having the same or similar peaks tothe peaks in these patterns fall into the scope of the invention. Aperson skilled in the art could compare the patterns as listed in theinvention with a pattern of any unknown crystal form, to prove whetherthe two patterns reveal the same or different crystal forms.

The terms “crystal forms” and “polycrystalline forms” and other relatedterms refer to the presence of solid compounds in a crystal structurewith a specific crystal form in the invention. Differences in physicaland chemical properties of the polycrystalline forms may be reflected inthe aspects of storage stability, compressibility, density, anddissolution rate. In an extreme case, differences in solubility anddissolution rate will result in drug inefficiency, even toxicity.

It should be illustrated that the values or numerical ranges asmentioned in the invention should not be narrowly understood as thevalues or numerical ranges per se, and a person skilled in the artshould understand them according to different specific technicalcircumstances. On the basis of no deviations of the spirits and rules ofthe invention, the specific values may vary. In the invention, suchfloating ranges that are predictable for a person skilled in the art areusually expressed by the wording “about”.

BRIEF DESCRIPTIONS OF THE DRAWINGS

FIG. 1 is the X-ray powder diffraction pattern of the crystal form I asprepared in Example 1 of the invention.

FIG. 2 is the DSC pattern of the crystal form I as prepared in Example 1of the invention.

FIG. 3 is the TGA pattern of the crystal form I as prepared in Example 1of the invention.

FIG. 4 is the X-ray powder diffraction pattern of the crystal form II asprepared in Example 4 of the invention.

FIG. 5 is the DSC pattern of the crystal form II as prepared in Example4 of the invention.

FIG. 6 is the TGA pattern of the crystal form II as prepared in Example4 of the invention.

FIG. 7 is the X-ray powder diffraction pattern of the crystal form IIIas prepared in Example 6 of the invention.

FIG. 8 is the DSC pattern of the crystal form III as prepared in Example6 of the invention.

FIG. 9 is the TGA pattern of the crystal form III as prepared in Example6 of the invention.

FIG. 10 is the X-ray powder diffraction pattern of the crystal form IVas prepared in Example 8 of the invention.

FIG. 11 is the DSC pattern of the crystal form IV as prepared in Example9 of the invention.

FIG. 12 is the TGA pattern of the crystal form IV as prepared in Example9 of the invention.

FIG. 13 is the X-ray powder diffraction pattern of the crystal form I asprepared in Example 2 of the invention.

FIG. 14 is the X-ray powder diffraction pattern of the crystal form I asprepared in Example 3 of the invention.

FIG. 15 is the X-ray powder diffraction pattern of the crystal form IIIas prepared in Example 7 of the invention.

FIG. 16 is the X-ray powder diffraction pattern of the crystal form IVas prepared in Example 9 of the invention.

FIG. 17 is the DVS pattern of the crystal form I of the invention.

FIG. 18 is the DVS pattern of the crystal form II of the invention.

FIG. 19 is the DVS pattern of the crystal form III of the invention.

FIG. 20 is the DVS pattern of the crystal form IV of the invention.

FIG. 21 is the diagram for showing the comparison in the XRPD patternsof the crystal form I according to the invention before and aftergrinding.

FIG. 22 is the diagram for showing the comparison in the XRPD patternsof the crystal form IV according to the invention before and aftergrinding.

FIG. 23 is the diagram for showing the comparison in the XPRD patternbetween the longer-term stability and acceleration stability of thecrystal form according to the invention.

FIG. 24 is the diagram for showing the comparison in the XPRD patternbetween the longer-term stability and acceleration stability of thecrystal form II according to the invention.

FIG. 25 is the diagram for showing the comparison in the XPRD patternbetween the longer-term stability and acceleration stability of thecrystal form III according to the invention.

FIG. 26 is the PSD pattern of the crystal form I of the invention.

FIG. 27 is the PSD pattern of the crystal form H of the invention.

FIG. 28 is the PSD pattern of the crystal form IV of the invention.

FIG. 29 is the PLM pattern of the crystal form I of the invention.

FIG. 30 is the PLM pattern of the crystal form II of the invention.

FIG. 31 is the PLM pattern of the crystal form IV of the invention.

DESCRIPTION OF EMBODIMENTS OF THE INVENTION

The invention is defined by further referring to the following examples.The examples describe in detail a method of preparing the crystal formsaccording to the invention and a method of using the same. It is obviousfor a person skilled in the art that variations to the material andmethods can be made in the case of no deviation from the scope of theinvention.

Apparatus and Methods as Used for Collecting Data:

The abbreviations as used in the invention are explained as follows:

XRPD: X-ray powder diffraction,

DSC: Differential scanning calorimetric analysis,

TGA: Thermogravimetric analysis,

DVS: Dynamic vapor sorption,

PSD: Particle size distribution,

PLM: Polarizing microscope

HPLC: High performance Liquid Chromatography

The X-ray powder diffraction pattern as described in the invention wascollected on a Panalytical Empyrean X-ray powder diffraction meter. TheX-ray powder diffraction method has the following parameters:

X-ray reflection parameters: Cu, Kα,

Kα1(Å): 1.540598; Kα2(Å): 1.544426,

Kα2/Kα1 intensity ratio: 0.50,

Voltage: 45 kilovolt (kV),

Current: 40 milliampere (mA),

Scanning scope: from 3.0° to 40.0°.

The differential scanning calorimetric (DSC) pattern as described in theinvention was collected on a TA Q2000. The differential scanningcalorimetric (DSC) method has the following parameters:

Scanning speed: 10° C./min,

Protective gas: nitrogen gas.

The thermogravimetric analysis (TGA) pattern as described in theinvention was collected on a TA Q500. The thermogravimetric analysis(TGA) method has the following parameters:

Scanning speed: 10° C./min,

Protective gas: nitrogen gas.

The dynamic vapor sorption (DVS) pattern as described in the inventionwas collected on an intrinsic dynamic vapor sorption meter as producedby Surface Measurement Systems Ltd. The dynamic vapor sorption methodhas the following parameters:

Temperature: 25° C.,

Loading gas, flowing speed: N₂, 200 ml/min,

Variation in mass per time: 0.002%/minute,

Relative humidity range: 0% RH-95% RH.

The particle size distribution (PSD) results as described in theinvention were collected on a S3500-type laser particle size analyticmeter as produced by Microtrac Company. The Microtrac S3500 is equippedwith a SDC (Sample Delivery Controller) feeding system. The test wasconducted via a wet process, and the dispersion medium as used in thetest was Isopar G. The laser particle size analytic meter has thefollowing parameters:

Particle size distribution: volume Collection time: 10 secondsdistribution Dispersion medium: Isopar G Particle size coordination:standard Collection frequency: 3 times Refractive index of dispersionmedium: 1.42 Transparency: transparent Residual: on Particle refractiveindex: 1.5 Flowing rate: 60* Particle shape: irregular Filtration: on*the flowing rate 60% is meant to 60% of the flowing rate 65 ml/second.

The high performance liquid chromatography (HPLC) data were collected inan Agilent 1260, and the used detector was a diode array detector (DAD).The HPLC method as described in the invention has the followingparameters:

1. Chromatographic column: Waters Xbridge C18 150×4.6 mm, 5 μm

2. Flowing phase: A: 0.1% trifluoro acetic acid aqueous solution

-   -   B: 0.1% trifluoro acetic acid solution in acetonitrile

The eluting gradient is shown in the following table:

Time (minute) % flowing phase B 0.0 10 3.0 10 20.0 90 25.0 90 25.1 1030.0 10

3. flowing rate: 1.0 mL/min

4. Injection volume: 5 μL

5. Detection wavelength: 254 nm

6. Column temperature: 40° C.

7. Diluent: 50% acetonitrile.

In the following examples, unless specifically stated, the term “roomtemperature” refers to the temperature range from 15 to 25° C.

The solids of crisaborole in free form used in the following examplescan be commercially available.

Example 1

202.5 mg of solids of crisaborole in free form were added to 6 mL of amixed solvent system (methanol: water, with the volume ratio 1:5), andthe resultant mixture was stirred at 50° C. for 5 days. The reactionmixture was subjected to centrifugal separation and vacuum dried at roomtemperature, to produce white solid crystals.

It was found that the resultant solid crystals were the crystal form Ias described in the invention by detection. The X-ray powder diffractionpattern of the crystal form is shown in FIG. 1, and the correspondingX-ray powder diffraction data are shown in Table 1.

Upon conducting the differential scanning calorimetric analysis, thecrystal form I, when being heated to a temperature in the vicinity of123° C., involved heat absorption peaks, and its DSC is shown in FIG. 2.Upon conducting the thermogravimetric analysis, the crystal form I, whenbeing heated to 120° C., had a mass lose gradient of about 4.2%, and itsTGA is shown in FIG. 3. The crystal form I according to the invention isa hydrate.

TABLE 1 2theta d-spacing Intensity % 5.98 14.79 21.09 11.98 7.39 2.6114.07 6.29 53.95 15.31 5.79 100.00 15.96 5.55 33.66 17.56 5.05 6.5318.14 4.89 42.95 21.34 4.16 26.11 24.86 3.58 39.83 26.09 3.42 65.7228.40 3.14 31.42 31.33 2.85 7.91 31.68 2.82 5.53 39.24 2.30 2.84

Example 2

51.4 mg of solids of crisaborole in free form were added to 1 mL ofacetonitrile solvent. After the solids were dissolved in the solvent,the solvent volatilized at room temperature when exposed to air until itcompletely volatilized, to produce white solid crystals.

It was found that the resultant solid crystals were the crystal form Ias described in the invention by detection, and the X-ray powderdiffraction data are shown in FIG. 13 and Table 2.

TABLE 2 2theta d-spacing Intensity % 5.99 14.76 5.42 12.02 7.36 1.0114.06 6.30 14.60 15.33 5.78 100.00 15.99 5.54 4.06 17.56 5.05 3.30 18.124.90 6.76 20.73 4.28 2.27 21.40 4.15 38.10 21.85 4.07 1.80 23.00 3.871.32 24.85 3.58 24.19 26.09 3.41 33.54 26.35 3.38 7.30 28.39 3.14 9.9929.05 3.07 3.25 30.94 2.89 6.24 31.35 2.85 3.33 31.68 2.82 2.59 32.662.74 4.91 33.69 2.66 2.40

The data in Table 3 were obtained by using the same method as describedin Example 2. A certain mass quantity of solids of crisaborole in freeform were added to a certain volume of solvent. After the solids weredissolved in the solvent, the solvent volatilized at room temperaturewhen exposed to air until the solvent completely volatilized, to producewhite solid crystals. The solids were checked by XRPD to be the crystalform I.

TABLE 3 Mass of raw Solvent Resultant crystal No. material (mg) Solventvolume (mL) form 1 13.1 Ethyl acetate 1.0 Crystal form I 2 13.0 Methyl(t- 1.0 Crystal form I butyl)ether 3 13.5 Chloroform 1.0 Crystal form I4 13.4 dichloromethane 1.0 Crystal form I

Example 3

30.7 mg of solids of crisaborole in free form were added to 1.5 mL ofwater solvent, and the resultant mixture was magnetically stirred atroom temperature for two days. The reaction mixture was subjected tocentrifugal separation and vacuum dried at room temperature, to producewhite solid crystals.

It was found that the resultant solid crystals were the crystal form Ias described in the invention by detection, and the X-ray powderdiffraction data of the crystal form are shown in FIG. 14 and Table 4.

TABLE 4 2theta d-spacing Intensity % 5.95 14.86 27.13 14.03 6.31 48.7415.28 5.80 100.00 15.93 5.56 34.94 18.12 4.90 41.14 21.33 4.16 24.5724.83 3.59 34.19 26.06 3.42 62.24 28.34 3.15 27.26 31.32 2.86 5.69 33.632.67 4.16

The data in Table 5 were obtained by using the same method as describedin Example 3. A certain mass quantity of solids of crisaborole in freeform were added to a certain volume of solvent, and the resultantmixture was magnetically stirred at room temperature. The reactionmixture was subjected to centrifugal separation and vacuum dried at roomtemperature, to produce white solid crystals. The resultant solids weredetermined by the XRPD to be the crystal form I.

TABLE 5 Mass of starting Solvent Resultant material volume crystal No.(mg) Solvent (mL) form 1 30.2 toluene 1.0 Crystal form I 2 31.6Acetonitrile/water 0.6/0.8 Crystal form I 3 30.8 Isopropyl acetate/water0.2/0.8 Crystal form I 4 29.6 1,4-dioxane/water 0.4/0.8 Crystal form I 530.5 Acetone/water 0.4/0.8 Crystal form I 6 29.9 Dimethylformamide/water 0.6/0.8 Crystal form I 7 29.8 Dimethyl sulfoxide/water0.6/0.8 Crystal form I 8 29.1 methylisobutylketone/n-heptane 0.6/0.5Crystal form I 9 30.3 Ethyl acetate/n-heptane 0.6/0.5 Crystal form I 1029.0 2-methyltetrahydrofuran/n-heptane 0.4/0.5 Crystal form I 11 30.3Chloroform/n-heptane 0.4/0.5 Crystal form I 12 31.4 ethanol/n-heptane0.2/1.3 Crystal form I 13 30.2 dichloromethane/toluene 0.4/0.5 Crystalform I 14 29.7 isopropanol/water 0.6/0.8 Crystal form I

Example 4

34.5 mg of solids of crisaborole in free form were added to 1.6 mL of amixed solvent system (methanol: water, with the volume ratio 1:1). Theresultant mixture was magnetically stirred at room temperature, and thenit was subjected to centrifugal separation and vacuum dried at roomtemperature, to produce white solid crystals.

It was found that the resultant solid crystals were the crystal form IIas described in the invention by detection. The X-ray powder diffractionpattern of the crystal form is shown in FIG. 4, and the correspondingX-ray powder diffraction data are shown in Table 6.

Upon conducting the differential scanning calorimetric analysis, thecrystal form II, when being heated to a temperature in the vicinity of134° C., involved heat absorption peaks, and its DSC is shown in FIG. 5.Upon conducting the thermogravimetric analysis, the crystal form II,when being heated to 115° C., had a mass lose gradient of about 4.2%,and its TGA is shown in FIG. 6. The crystal form II according to theinvention is a hydrate.

TABLE 6 2theta d-spacing Intensity % 7.01 12.61 2.38 12.17 7.27 3.5014.21 6.23 4.68 14.77 6.00 1.50 16.55 5.36 37.69 17.60 5.04 9.92 18.324.84 8.97 20.76 4.28 100.00 21.35 4.16 11.45 21.75 4.09 11.77 22.55 3.9419.21 23.08 3.85 6.09 23.43 3.80 4.61 25.97 3.43 4.66 27.00 3.30 2.7527.89 3.20 24.06 28.65 3.12 3.74 30.03 2.98 3.15 31.44 2.85 4.29 37.292.41 2.50

Example 5

30.3 mg of solids of crisaborole in free form were added to 0.4 mL ofisopropanol solvent, and 0.6 mL of the reverse solvent water weredropwise added thereto while being magnetically stirred at roomtemperature. The resultant mixture crystallized while being stirred for5 days, and then it was subjected to centrifugal separation and vacuumdried at room temperature, to produce white solid crystals.

It was found that the resultant solid crystals were the crystal form IIas described in the invention by detection, and the X-ray powderdiffraction data of the crystal form are shown in Table 7.

TABLE 7 2theta d-spacing Intensity % 12.24 7.23 7.02 14.30 6.19 7.6815.55 5.70 4.38 16.62 5.33 65.89 17.64 5.03 11.91 18.39 4.82 12.60 19.964.45 2.68 20.80 4.27 100.00 21.42 4.15 11.19 21.76 4.08 12.83 22.58 3.9439.24 23.08 3.85 10.59 23.51 3.78 7.85 24.13 3.69 3.90 24.86 3.58 9.9526.03 3.42 6.30 27.03 3.30 4.79 27.90 3.20 26.46 28.69 3.11 4.04 31.462.84 6.90

The data in Table 8 were obtained by using the same method as describedin the example. A certain mass quantity of solids of crisaborole in freeform were added to a certain volume of a positive solvent, and a certainvolume of a reverse solvent was dropwise added thereto at roomtemperature while being magnetically stirred. The resultant mixturecrystallized while being stirred, and then it was subjected tocentrifugal separation and vacuum dried, to produce white solidcrystals. The solids were determined by XRPD to be the crystal form II.

TABLE 8 Mass of Volume of Volume of Whether or starting positive reversenot solids Resultant material Positive solvent Reverse solvent arecrystal No. (mg) solvent (mL) solvent (mL) precipitated form 1 32.4acetone 0.2 water 0.2 Yes Crystal form II 2 29.6 1,4-dioxane 0.2 water0.2 Yes Crystal form II 3 29.5 tetrahydrofuran 0.2 water 0.4 Yes Crystalform II 4 28.8 dimethylformamide 0.2 water 0.4 Yes Crystal form II 528.5 Dimethyl 0.2 water 0.4 Yes Crystal sulfoxide form II

Example 6

200.5 mg of solids of crisaborole in free form were charged into a 20 mLglass bottle loaded with 5 mL of solvent acetone, and dissolved untilthe resultant mixture was clear. The opening of the bottle was sealedwith a sealing membrane, and the membrane was pinked with a needle toform several small holes. The bottle was placed at room temperature toallow the solvent to slowly volatize, thereby to produce white solidcrystals.

It was found that the resultant solid crystals were the crystal form IIIas described in the invention by detection. The X-ray powder diffractionpattern of the crystal form is shown in FIG. 7, and the correspondingX-ray powder diffraction data are shown in Table 9.

Upon conducting the differential scanning calorimetric analysis, thecrystal form III, when being heated to a temperature in the vicinity of136° C., involved heat absorption peaks, and its DSC is shown in FIG. 8.Upon conducting the thermogravimetric analysis, the crystal form III,when being heated to 145° C., had a mass lose gradient of about 2.5%,and its TGA is shown in FIG. 9. The crystal form III according to theinvention is a hydrate.

TABLE 9 2theta d-spacing Intensity % 10.20 8.67 1.03 13.63 6.49 1.1916.21 5.47 7.54 17.55 5.05 3.06 18.24 4.86 2.64 18.62 4.77 8.91 19.584.53 3.64 20.59 4.31 100.00 20.72 4.29 91.97 21.30 4.17 12.98 21.69 4.107.34 22.49 3.95 2.14 23.70 3.75 2.18 23.95 3.72 1.80 26.29 3.39 2.0426.50 3.36 2.82 26.93 3.31 2.79 27.41 3.25 2.88 27.86 3.20 22.34 31.382.85 5.26 37.17 2.42 1.12

Example 7

11.5 mg of solids of crisaborole in free form were added to 0.2 ofacetone solvent, and the solvent volatilized at room temperature untilit completely volatilized, to produce white solid crystals.

It was found that the resultant solid crystals were the crystal form IIIas described in the invention by detection. The X-ray powder diffractiondata of the crystal form are shown in FIG. 15 and Table 10.

TABLE 10 2theta d-spacing Intensity % 13.66 6.48 16.96 15.63 5.67 3.6716.43 5.40 13.85 18.22 4.87 8.94 18.62 4.76 27.66 19.54 4.54 14.45 20.584.32 100.00 21.26 4.18 5.22 21.70 4.10 10.34 22.54 3.94 6.87 23.74 3.7519.42 26.01 3.43 2.08 27.67 3.22 67.83 28.51 3.13 3.66 31.19 2.87 3.7837.12 2.42 3.30

Example 8

About 5 mg of crisaborole in free form were placed in a DSC(Q2000) tray,and the heating program was set as follows: the solids were heated tothe temperature of 90° C., in a rate of 10° C./min; the solids wereheated to the temperature of 130° C., in a rate of 5° C./min. The solidswere balanced for 5 minutes, to produce white solid crystals.

It was found that the resultant solid crystals were the crystal form IVas described in the invention by detection. The X-ray powder diffractiondata of the crystal form are shown in FIG. 10 and Table 11.

TABLE 11 2theta d-spacing Intensity % 5.34 16.54 44.99 12.42 7.13 16.4613.01 6.80 34.31 15.12 5.86 9.66 15.72 5.64 9.34 16.20 5.47 16.87 17.195.16 52.62 17.47 5.08 44.48 18.56 4.78 92.02 19.29 4.60 6.44 19.98 4.44100.00 20.50 4.33 6.81 20.90 4.25 2.46 21.36 4.16 33.74 21.67 4.10 12.7422.39 3.97 5.76 23.14 3.84 41.01 23.73 3.75 16.09 24.88 3.58 70.56 25.623.48 6.62 26.33 3.39 90.16 27.56 3.24 7.25 29.11 3.07 2.09 30.24 2.9610.28 31.03 2.88 6.06 33.02 2.71 1.14 36.13 2.49 1.37

Example 9

About 11.5 mg of crisaborole in free form were weighted and charged intoa glass bottle loaded with 0.2 mL of acetone solvent, and the resultantmixture volatilized at room temperature when exposed to air until thesolvent completely volatilized. The precipitated solids were placed in aDSC(Q2000) tray, and the heating program was set as follows: the solidswere heated to the temperature of 90° C., in a rate of 10° C./min; thesolids were heated to the temperature of 145° C., in a rate of 5°C./min. The solids were balanced for 5 minutes, to produce white solidcrystals.

It was found that the resultant solid crystals were the crystal form IVas described in the invention. The X-ray powder diffraction pattern ofthe crystal form is shown in FIG. 16 and the X-ray powder diffractiondata of the crystal form are shown Table 12.

Upon conducting the differential scanning calorimetric analysis, thecrystal form IV, when being heated to a temperature in the vicinity of172° C., involved heat absorption peaks, and its DSC is shown in FIG.11. Upon conducting the thermogravimetric analysis, the crystal form IV,when being heated to 150° C., had a mass lose gradient of about 1.4%,and its TGA is shown in FIG. 12. The crystal form IV according to theinvention is an anhydrate.

TABLE 12 2theta d-spacing Intensity % 5.35 16.53 59.32 11.50 7.69 8.6312.47 7.10 13.07 13.01 6.80 25.27 15.75 5.63 12.05 17.22 5.15 33.7318.58 4.78 80.18 20.03 4.43 100.00 21.39 4.15 28.17 23.21 3.83 34.7223.74 3.75 17.17 24.91 3.57 53.77 26.39 3.38 86.10 27.62 3.23 9.18Test Part

Experimental Example 1 Study of Moisture Absorption

About 10 mg of the crystal form I, crystal form II, crystal form III andcrystal form IV according to the invention were taken respectively toperform the dynamic vapor sorption (DVS) test. The obtained results wereshown in Table 13:

TABLE 13 Relative humidity Weight Weight increase of 80% Weight increaseof 95% increase (%) relative humidity relative humidity Crystal form I0.14% 0.32% Crystal form II 0.13% 0.32% Crystal form III 0.09% 0.15%Crystal form IV 1.53% 4.90%

The DVS patterns of the crystal form I, crystal form II, crystal formIII and crystal form IV are respectively shown in FIG. 17, FIG. 18, FIG.19 and FIG. 20.

With regard to the descriptions for the moisture absorptioncharacteristic and the definition for the increased weight of moistureabsorption (Guidelines for the Moisture Absorption Tests of Drugs in theAppendix of Chinese Pharmacopoeia (2015), Experimental conditions: 25°C.±1° C., 80% relative humidity):

Deliquescence: enough moisture is absorbed to form a liquid

High moisture absorption: the increased weight as caused by absorbingmoisture is not less than 15.0%

Moisture absorption: the increased weight as caused by absorbingmoisture is less than 15.0% but not less than 2.0%

Slight moisture absorption: the increased weight as caused by absorbingmoisture is less than 2.0% but not less than 0.2%

No or almost no moisture absorption: the increased weight as caused byabsorbing moisture is less than 0.2%.

The results show that according to the standards in ChinesePharmacopoeia (2015), the crystal form I, crystal form II, and crystalform III of the invention almost have no moisture absorption, and thecrystal IV has slight moisture absorption. Thus, each of the abovecrystal forms will not be ready to be influenced by high moisture so asto take the deliquescence. Particularly, even under the condition thatthe relative humidity was up to 95%, the crystal form I, crystal formII, and crystal form III of the invention still each have a lowincreased weight as caused by absorbing moisture, and thus they havemore excellent deliquescence resistance.

Experimental Example 2 Study of Mechanical Stability

The crystal form I and crystal form IV of the invention wererespectively placed in a mortar, and they were ground for 5 minutes byhand. The XRPD of the ground solids was tested, and the results wereshown in Table 14:

TABLE 14 Starting crystal form Final crystal form Crystal form I Crystalform I Crystal form IV Crystal form IV

The results show that under the action of certain mechanical stress, thecrystal form I and crystal form IV of the invention are not changed, andthey still can maintain stable physical and chemical properties. Thediagrams for showing the comparison of the XRPD patterns before andafter grinding of the crystal form I and the crystal form IV arerespectively shown in FIG. 21 and FIG. 22 (the upper figure is the XRPDpattern before grinding, and the lower figure is the XRPD pattern aftergrinding for 5 minutes.

Experimental Example 3 Study of Dynamic Solubility

Samples of the crystal form I, crystal form II, crystal form III andcrystal form IV of the invention were respectively formulated into asaturated solution with a fasting stimulated intestinal fluid (FaSSIF)with a pH of 6.5, a feeding state stimulated intestinal fluid (FeSSIF)with a pH of 5.0, a stimulated gastric fluid (SGF) with a pH of 1.8, andwater, and the high performance liquid chromatography (HPLC) was used torespectively measure the amounts of compounds in the solutions at 1 h, 4h and 24 h. The results are shown in Table 15.

TABLE 15 FaSSIF (pH = 6.5) FeSSIF (pH = 5.0) Time Crystal CrystalCrystal Crystal Crystal Crystal Crystal Crystal (h) form I form II formIII form IV form I form II form III form IV Solubility (mg /ml) 1 0.0060.011 0.008 0.009 0.044 0.018 0.025 0.062 4 0.007 0.005 0.010 0.0170.059 0.049 0.067 0.061 24 0.012 0.008 0.012 0.013 0.059 0.055 0.0740.056 SGF (pH = 1.8) H₂O Time Crystal Crystal Crystal Crystal CrystalCrystal Crystal Crystal (h) form I form II form III form IV form I formII form III form IV Solubility (mg /ml) 1 0.011 0.010 0.033 0.031 0.0040.003 0.005 ND 4 0.037 0.026 0.034 0.027 0.005 0.001 0.004 0.006 240.038 0.015 0.040 0.026 0.006 0.006 0.006 0.004 ND: un-detected.

The crystal form I, crystal form II, crystal form III and crystal formIV of the invention each have a solubility that is in line withmedicinal requirements.

Experimental Example 4 Study of Long-Term and Acceleration Stabilities

Samples of the crystal form I, crystal form II, and crystal form III ofthe invention were respectively placed under the conditions of 25° C.and a 60% relative humidity, and under the conditions of 40° C. and a75% relative humidity, and the results of the changes in the crystalform are shown in Table 16:

TABLE 16 Starting crystal Storage Storage form condition time Changes ofcrystal form Crystal form I 25° C. 60% 3 months Crystal form I remainedrelative humidity unchanged Crystal form I 40° C. 75% 3 months Crystalform I remained relative humidity unchanged Crystal form II 25° C. 60% 3months Crystal form II remained relative humidity unchanged Crystal formII 40° C. 75% 3 months Crystal form II remained relative humidityunchanged Crystal form III 25° C. 60% 3 months Crystal form III remainedrelative humidity unchanged Crystal form III 40° C. 75% 3 months Crystalform III remained relative humidity unchanged

The results show that the crystal form I, crystal form II and crystalform III of the invention can still maintain their stability placed inthe two kinds of humidity for 3 months. The XRPD diagrams for showingthe comparisons in the long-term and acceleration stabilities of thecrystal form I, crystal form II, and crystal form III of the inventionare respectively shown in FIG. 23, FIG. 24 and FIG. 25 (in each figure,the upper pattern shows the XRPD pattern of the crystal forms before thestorage, the middle pattern shows the XRPD pattern of the crystal formsafter 3 months by being placed under the storage conditions of 25° C.and a 60% relative humidity, and the lower pattern shows the XRPDpattern of the crystal forms after 3 months by being placed under theconditions of 40° C. and a 75% relative humidity).

Experimental Example 5 Study of Particle Size Distribution Particle SizeComparative Test:

Samples of the crystal form I, crystal form II, crystal form III, andcrystal form IV of the invention were taken to carry out the particlesize distribution test.

The results of the particle size distribution are shown in Table 17:

TABLE 17 Crystal form MV (μm) D10 (μm) D50 (μm) D90 (μm) Crystal form I9.62 1.69 5.52 20.35 Crystal form II 23.13 8.24 20.46 40.42 Crystal formIII 289.0 21.68 163.0 903.1 Crystal form IV 52.95 13.43 33.68 99.36Note:

MV represents average particle size as calculated in terms of the volume

D10 represents the particle size corresponding to 10% of the particlesize distribution (volume distribution).

D50 represents the particle size corresponding to 50% of the particlesize distribution (volume distribution), also called as median size.

D90 represents the particle size corresponding to 90% of the particlesize distribution (volume distribution).

The PSD patterns of the crystal form I, the crystal form II and thecrystal form IV are respectively shown in FIG. 26, FIG. 27 and FIG. 28,and from these figures, it can be seen that the particle sizedistributions of the crystal form I, the crystal form II and the crystalform IV are homogeneous.

In addition, the PLM patterns of the crystal form I, the crystal form IIand the crystal form IV are respectively shown in FIG. 29, FIG. 30 andFIG. 31, and from these figures, it can be seen that the particle sizesof the particles of the crystal form I, the crystal form II and thecrystal form IV are homogeneous.

The homogenous particle size can help to simplify the post-treatmentprocesses of the formulation, and to increase quantity controls.

A person skilled in the art could understand that under the teachings ofthe description, some variations or changes to the invention areallowable. These variations and changes also should be in the scope asdefined by the claims in the invention.

The invention claimed is:
 1. A crystalline Form I of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 14.1°±0.2°, 15.3°±0.2°, and 26.1°±0.2°, degrees two theta.
 2. Acrystalline Form I of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 16.0°±0.2°, 18.1°±0.2° and 24.8°±0.2°, degrees two theta.
 3. Acrystalline Form I of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 6.0°±0.2°, 21.4°±0.2° and 28.4°±0.2°, degrees two theta.
 4. Thecrystalline Form I of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to claim 1 wherein the X-ray powder diffraction patternfurther comprising diffraction peaks at 16.0°±0.2°, 18.1°±0.2°, and24.8°±0.2°, degrees two theta.
 5. The crystalline Form I of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to claim 1 wherein the X-ray powder diffraction patternfurther comprising diffraction peaks at 6.0°±0.2°, 16.0°±0.2°,18.1°±0.2°, 21.4°±0.2°, 24.8°±0.2°, and 28.4°±0.2°, degrees two theta.6. A pharmaceutical composition comprising the crystalline Form I of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to any one of claims 1 to 5 and at least one pharmaceuticallyacceptable carrier or vehicle.
 7. A crystalline Form II of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 16.6°±0.2°, 20.8°±0.2°, and 22.6°±0.2°, degrees two theta.
 8. Acrystalline Form II of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 17.6°±0.2°, 21.8°±0.2° and 27.9°±0.2°, degrees two theta.
 9. Acrystalline Form II of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 18.4°±0.2°, 21.4°±0.2°, and 23.1°±0.2°, degrees two theta.
 10. Thecrystalline Form II of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to claim 7 wherein the X-ray powder diffraction patternfurther comprising diffraction peaks at 17.6°±0.2°, 21.8°±0.2° and27.9°±0.2°, degrees two theta.
 11. The crystalline Form II of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to claim 7 wherein the X-ray powder diffraction patternfurther comprising diffraction peaks at 17.6°±0.2°, 18.4°±0.2°,21.4°±0.2°, 21.8°±0.2°, 23.1°±0.2° and 27.9°±0.2°, degrees two theta.12. A pharmaceutical composition comprising the crystalline Form II of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to any one of claims 7 to 11 and at least one pharmaceuticallyacceptable carrier or vehicle.
 13. A crystalline Form III of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 18.6°±0.2°, 20.6°±0.2° and 27.8°±0.2°, degrees two theta.
 14. Acrystalline Form III of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 13.6±0.2°, 19.5°±0.2° and 21.7°±0.2°, degrees two theta.
 15. Acrystalline Form III of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrilehaving an X-ray powder diffraction pattern comprising diffraction peaksat 16.3°±0.2°, 21.3°±0.2°, and 22.5°±0.2°, degrees two theta.
 16. Thecrystalline Form III of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to claim 13 wherein the X-ray powder diffraction patternfurther comprising diffraction peaks at 13.6°±0.2°, 19.5°±0.2°, and21.7°±0.2°, degrees two theta.
 17. The crystalline Form III of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to claim 13 wherein the X-ray powder diffraction patternfurther comprising diffraction peaks at 13.6°±0.2°, 16.3°±0.2°,19.5°±0.2°, 21.3°±0.2°, 21.7°±0.2°, and 22.5°±0.2°, degrees two theta.18. A pharmaceutical composition comprising the crystalline Form III of4-[(1,3-dihydro-1-hydroxyl-2,1-benzoxaborolane-5-yl)oxy]benzonitrileaccording to any one of claims 13 to 17 and at least onepharmaceutically acceptable carrier or vehicle.